Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1219771

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1219771

Europe Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 85 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Europe Bronchodilators Market would witness market growth of 4.4% CAGR during the forecast period (2022-2028).

Corticosteroids commonly inhaled are added to beta-2 agonists to decrease pro-inflammatory agents and inflammation that further constrict airways. Beta-2 agonist class bronchodilators do not affect the underlying pathology of lung disease; they are only symptomatic treatments. Hence, adding inhaled corticosteroids to the regimen has been the mainstay of mild to moderate reversible lung diseases with or without long-acting beta-2 agonists. Anticholinergics are the final class of medicine that are considered bronchodilators.

This class's mechanism inhibits the effects of the parasympathetic nervous system medicated by the vagus nerve. A hyperactive parasympathetic nervous system causes airways and bronchial secretions to narrow. Medicines that inhibit the actions of the parasympathetic nervous system at the airway's low level will create a bronchodilatory effect.

These medicines include tiotropium bromide, which has a more prolonged effect of up to 24 hours, and ipratropium bromide, a short-acting medication that works for around 4 to 6 hours. Anticholinergics' primary function in the setting of chronic obstructive pulmonary disease. Patients with asthma can generally control their symptoms with a corticosteroid and a beta-2 agonist.

In England, smoking is one of the primary causes of health inequalities, with the harm focused on disadvantaged groups and communities. In 2019, around 13.9% of adults in England still smoked, approximately 6 million people. Smoking is one of the leading preventable causes of illness and premature death, responsible for around 74,600 deaths in England. In addition, one in 4 patients in a hospital bed is a smoker. The rising number of tobacco consumers will also increase the number of lung-based diseases and thereby surge the usage of medication like bronchodilators for their treatments, boosting the market growth in the region.

The Germany market dominated the Europe Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,671.7 million by 2028. The UK market is exhibiting a CAGR of 3.5% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.2% during (2022 - 2028).

Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Beta-Adrenergic
  • Xanthine Derivatives
  • Anticholinergic

By Route of Administration

  • Nasal (Inhalable)
  • Oral
  • Injectable

By Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled

  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Cipla Limited
  • Viatris, Inc.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Europe Bronchodilators Market, by Drug Class
    • 1.4.2 Europe Bronchodilators Market, by Route of Administration
    • 1.4.3 Europe Bronchodilators Market, by Disease
    • 1.4.4 Europe Bronchodilators Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Europe Bronchodilators Market by Drug Class

  • 3.1 Europe Beta-Adrenergic Market by Country
  • 3.2 Europe Xanthine Derivatives Market by Country
  • 3.3 Europe Anticholinergic Market by Country

Chapter 4. Europe Bronchodilators Market by Route of Administration

  • 4.1 Europe Nasal (Inhalable) Market by Country
  • 4.2 Europe Oral Market by Country
  • 4.3 Europe Injectable Market by Country

Chapter 5. Europe Bronchodilators Market by Disease

  • 5.1 Europe Asthma Market by Country
  • 5.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
  • 5.3 Europe Others Market by Country

Chapter 6. Europe Bronchodilators Market by Country

  • 6.1 Germany Bronchodilators Market
    • 6.1.1 Germany Bronchodilators Market by Drug Class
    • 6.1.2 Germany Bronchodilators Market by Route of Administration
    • 6.1.3 Germany Bronchodilators Market by Disease
  • 6.2 UK Bronchodilators Market
    • 6.2.1 UK Bronchodilators Market by Drug Class
    • 6.2.2 UK Bronchodilators Market by Route of Administration
    • 6.2.3 UK Bronchodilators Market by Disease
  • 6.3 France Bronchodilators Market
    • 6.3.1 France Bronchodilators Market by Drug Class
    • 6.3.2 France Bronchodilators Market by Route of Administration
    • 6.3.3 France Bronchodilators Market by Disease
  • 6.4 Russia Bronchodilators Market
    • 6.4.1 Russia Bronchodilators Market by Drug Class
    • 6.4.2 Russia Bronchodilators Market by Route of Administration
    • 6.4.3 Russia Bronchodilators Market by Disease
  • 6.5 Spain Bronchodilators Market
    • 6.5.1 Spain Bronchodilators Market by Drug Class
    • 6.5.2 Spain Bronchodilators Market by Route of Administration
    • 6.5.3 Spain Bronchodilators Market by Disease
  • 6.6 Italy Bronchodilators Market
    • 6.6.1 Italy Bronchodilators Market by Drug Class
    • 6.6.2 Italy Bronchodilators Market by Route of Administration
    • 6.6.3 Italy Bronchodilators Market by Disease
  • 6.7 Rest of Europe Bronchodilators Market
    • 6.7.1 Rest of Europe Bronchodilators Market by Drug Class
    • 6.7.2 Rest of Europe Bronchodilators Market by Route of Administration
    • 6.7.3 Rest of Europe Bronchodilators Market by Disease

Chapter 7. Company Profiles

  • 7.1 Glenmark Pharmaceuticals Limited
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Research & Development Expenses
    • 7.1.4 Recent strategies and developments:
      • 7.1.4.1 Product Launches and Product Expansions:
  • 7.2 Merck & Co., Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 GlaxoSmithKline PLC
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expense
  • 7.4 AstraZeneca PLC
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional Analysis
    • 7.4.4 Research & Development Expenses
  • 7.5 Teva Pharmaceutical Industries Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Regional Analysis
    • 7.5.4 Research & Development Expenses
  • 7.6 Cipla Limited
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expense
  • 7.7 Viatris, Inc. (Mylan N.V.)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Boehringer Ingelheim International Gmbh
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Regional & Segmental Analysis
    • 7.9.4 Research & Development Expenses
  • 7.10. Sun Pharmaceutical Industries Ltd.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Regional & Segmental Analysis
    • 7.10.4 Research & Development Expenses

LIST OF TABLES

  • TABLE 1 Europe Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 2 Europe Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 3 Europe Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 4 Europe Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 5 Europe Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 6 Europe Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 7 Europe Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 8 Europe Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 9 Europe Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 10 Europe Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 11 Europe Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 12 Europe Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 13 Europe Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 14 Europe Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 15 Europe Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 16 Europe Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 17 Europe Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 18 Europe Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 19 Europe Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 20 Europe Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 21 Europe Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 22 Europe Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 23 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 24 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 25 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 26 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 27 Europe Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 28 Europe Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 29 Germany Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 30 Germany Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 31 Germany Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 32 Germany Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 33 Germany Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 34 Germany Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 35 Germany Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 36 Germany Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 37 UK Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 38 UK Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 39 UK Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 40 UK Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 41 UK Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 42 UK Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 43 UK Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 44 UK Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 45 France Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 46 France Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 47 France Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 48 France Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 49 France Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 50 France Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 51 France Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 52 France Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 53 Russia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 54 Russia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 55 Russia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 56 Russia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 57 Russia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 58 Russia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 59 Russia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 60 Russia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 61 Spain Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 62 Spain Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 63 Spain Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 64 Spain Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 65 Spain Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 66 Spain Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 67 Spain Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 68 Spain Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 69 Italy Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 70 Italy Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 71 Italy Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 72 Italy Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 73 Italy Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 74 Italy Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 75 Italy Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 76 Italy Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 77 Rest of Europe Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 78 Rest of Europe Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 79 Rest of Europe Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 80 Rest of Europe Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 81 Rest of Europe Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 82 Rest of Europe Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 83 Rest of Europe Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 84 Rest of Europe Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 85 Key Information - Glenmark Pharmaceuticals Limited
  • TABLE 86 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 87 Key Information - GlaxoSmithKline PLC
  • TABLE 88 KEY INFORMATION - AstraZeneca PLC
  • TABLE 89 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 90 Key Information - Cipla Limited
  • TABLE 91 key information - Viatris, Inc.
  • TABLE 92 Key Information - Novartis AG
  • TABLE 93 Key Information - Boehringer Ingelheim International GmbH
  • TABLE 94 Key Information - Sun Pharmaceutical Industries Ltd.

List of Figures

  • FIG 1 Methodology for the research
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!